Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients.

Kofler, S; Deutsch, MA; Bigdeli, AK; Shvets, N; Vogeser, M; Mueller, TH; Meiser, B; Steinbeck, G; Reichart, B; Kaczmarek, I

doi:10.1016/j.healun.2009.03.006

journal article

Dokumenttyp:: Controlled Clinical Trial; Journal Article; Article
Autor(en):: Kofler, S; Deutsch, MA; Bigdeli, AK; Shvets, N; Vogeser, M; Mueller, TH; Meiser, B; Steinbeck, G; Reichart, B; Kaczmarek, I
Titel:: Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients.
Abstract:: Proton pump inhibitors (PPIs) are often prescribed for gastrointestinal discomfort after heart transplantation (HTx). This study investigates the impact of PPI use on mycophenolate acid (MPA) pharmacokinetics in heart transplant recipients receiving mycophenolate mofetil (MMF) and tacrolimus (Tac).MPA post-dose plasma concentrations at 0 to 2 hours were obtained by high-performance liquid chromatography (HPLC) in 21 patients on pantoprazole 40 mg/day (PPI group) and 12 patients not on pantoprazole (control group). In a subgroup, MPA plasma concentrations at 0 to 12 hours were measured to evaluate full MPA area-under-the-curve (AUC) measurements.In the PPI group, the mean daily MMF dose was 1,912 +/- 1,023 mg with mean pre-dose serum concentrations (C(0)) of 1.9 +/- 1.4 mg/liter, without a significant difference from controls. Mean post-dose MPA concentrations at 30 minutes (C(0.5h)) were significantly higher in the control group (control, 17.9 +/- 11.5 mg/liter; PPI, 6.7 +/- 4.6 mg/liter; p < 0.001). One- and 2-hour (C(1h, 2h)) MPA concentrations were persistently higher in the control group (1 hour: control, 13.8 +/- 9.1 mg/liter; PPI, 7.7 +/- 4.1 mg/liter; 2 hours: control, 7.6 +/- 4.2; PPI, 5.0 +/- 2.8 mg/liter; p < 0.05). In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3.3 +/- 2.4 mg/liter; PPI, 1.6 +/- 1.3 mg/liter; p < 0.05) and a significantly higher dose-adjusted AUC C(0-3h) (control, 59.5 +/- 20.7 mg/liter; PPI, 41.7 +/- 23.4 mg/liter; p < 0.05). In the subgroup, the maximum plasma concentration of mycophenolic acid (MPA C(max)) in the PPI group was significantly lower (10.1 +/- 4.7 mg/liter) than in the control group (45.5 +/- 53.5 mg/liter, p < 0.0001), whereas t(max) revealed no differences (control: 1.1 +/- 0.77 hours; PPI: 1.1 +/- 0.97 hours). Furthermore, a clear trend for more acute rejection episodes (AREs) and more transplant vasculopathy (TVP) was found in the PPI group.Patients with PPI co-medication show significantly lower MPA plasma concentrations, possibly due to decreased absorption. Therapeutic drug monitoring allows identification of patients with decreased MMF drug exposure who might be at risk for acute rejection.
Zeitschriftentitel:: J Heart Lung Transplant
Jahr:: 2009
Band / Volume:: 28
Heft / Issue:: 6
Seitenangaben Beitrag:: 605-11
Sprache:: eng
Volltext / DOI:: doi:10.1016/j.healun.2009.03.006
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/19481022
Print-ISSN:: 1053-2498
TUM Einrichtung:: Klinik für Herz- und Gefäßchirurgie (Prof. Lange)
BibTeX

Vorkommen:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Lehr- und Forschungskooperationen mit den Kliniken und Instituten am Deutschen Herzzentrum Klinik für Herz- und Gefäßchirurgie (DHM) (Prof. Krane)2009